258 related articles for article (PubMed ID: 15136407)
1. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
Cunha BA
Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407
[TBL] [Abstract][Full Text] [Related]
2. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
3. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
4. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
5. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials.
Skalsky K; Yahav D; Lador A; Eliakim-Raz N; Leibovici L; Paul M
Clin Microbiol Infect; 2013 Apr; 19(4):370-8. PubMed ID: 22489673
[TBL] [Abstract][Full Text] [Related]
6. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Piso RJ; Arnold C; Bassetti S
Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
[TBL] [Abstract][Full Text] [Related]
7. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
[TBL] [Abstract][Full Text] [Related]
8. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
Teh B; Grayson ML; Johnson PD; Charles PG
Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
[TBL] [Abstract][Full Text] [Related]
9. Appropriate outpatient macrolide use in community-acquired pneumonia.
Gotfried MH
J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
[TBL] [Abstract][Full Text] [Related]
10. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
11. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
Stahl JE; Barza M; DesJardin J; Martin R; Eckman MH
Arch Intern Med; 1999 Nov; 159(21):2576-80. PubMed ID: 10573047
[TBL] [Abstract][Full Text] [Related]
12. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
Garin N; Nendaz M
Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
14. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
15. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.
Epstein BJ; Gums JG
Drugs; 2005; 65(14):1949-71. PubMed ID: 16162020
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based medicine: empiric antibiotic therapy in community-acquired pneumonia.
Read RC
J Infect; 1999 Nov; 39(3):171-8. PubMed ID: 10714789
[TBL] [Abstract][Full Text] [Related]
18. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
19. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
20. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.
Uranga A; España PP; Bilbao A; Quintana JM; Arriaga I; Intxausti M; Lobo JL; Tomás L; Camino J; Nuñez J; Capelastegui A
JAMA Intern Med; 2016 Sep; 176(9):1257-65. PubMed ID: 27455166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]